ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.405
-0.085 (-5.70%)
Mar 31, 2025, 1:15 PM EDT - Market open
ADC Therapeutics Revenue
In the year 2024, ADC Therapeutics had annual revenue of $70.84M with 1.84% growth. ADC Therapeutics had revenue of $16.91M in the quarter ending December 31, 2024, with 0.71% growth.
Revenue (ttm)
$70.84M
Revenue Growth
+1.84%
P/S Ratio
2.04
Revenue / Employee
$267,309
Employees
265
Market Cap
139.21M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ADCT News
- 4 days ago - ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 days ago - ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update - PRNewsWire
- 5 days ago - ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - PRNewsWire
- 6 days ago - ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 - Seeking Alpha
- 11 days ago - ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 - PRNewsWire
- 7 weeks ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 2 months ago - ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - PRNewsWire
- 3 months ago - ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PRNewsWire